HDL therapy today: from atherosclerosis, to stent compatibility to heart failure
- 17 November 2019
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 51 (7-8) , 345-359
Abstract
Epidemiologically, high-density lipoprotein (HDL) cholesterol levels have been inversely associated to cardiovascular (CV) events, although a Mendelian Randomization Study had failed to establish a clear causal role. Numerous atheroprotective mechanisms have been attributed to HDL, the main being the ability to promote cholesterol efflux from arterial walls; anti-inflammatory effects related to HDL ligands such as S1P (sphingosine-1-phosphate), resolvins and others have been recently identified. Experimental studies and early clinical investigations have indicated the potential of HDL to slow progression or induce regression of atherosclerosis. More recently, the availability of different HDL formulations, with different phospholipid moieties, has allowed to test other indications for HDL therapy. Positive reports have come from studies on coronary stent biocompatibility, where the use of HDL from different sources reduced arterial cell proliferation and thrombogenicity. The observation that low HDL-C levels may be associated with an enhanced risk of heart failure (HF) has also suggested that HDL therapy may be applied to this condition. HDL infusions or apoA-I gene transfer were able to reverse heart abnormalities, reduce diastolic resistance and improve cardiac metabolism. HDL therapy may be effective not only in atherosclerosis, but also in other conditions, of relevant impact on human health.Keywords
This publication has 137 references indexed in Scilit:
- Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Macrophages Increases Inflammation and Accelerates Atherosclerosis in MiceCirculation Research, 2013
- Lipid Lowering and HDL Raising Gene Transfer Increase Endothelial Progenitor Cells, Enhance Myocardial Vascularity, and Improve Diastolic FunctionPLOS ONE, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Anti-atherogenic mechanisms of high density lipoprotein: Effects on myeloid cellsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusionBasic Research in Cardiology, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Relations of Lipid Concentrations to Heart Failure IncidenceCirculation, 2009
- Macrophage Reverse Cholesterol Transport in Mice Expressing ApoA-I MilanoArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Increased Inflammatory Gene Expression in ABC Transporter–Deficient MacrophagesCirculation, 2008
- Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic MiceJACC, 2006